Management of Hepatocellular Carcinoma in Japan as a World-Leading Model
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - December 12, 2017 Category: Cancer & Oncology Source Type: research

Short-Term Outcomes following Hepatectomy in Elderly Patients with Hepatocellular Carcinoma: An Analysis of 10,805 Septuagenarians and 2,381 Octo- and Nonagenarians in Japan
We examined the safety of hepatectomy in octogenarians and nonagenarians using large-scale data from the Diagnosis Procedure Combination database, a national administrative database in Japan.Method: We conducted a survey to collect data for all inpatients from 2007 and 2012. We identified 27,094 patients who underwent hepatectomy for HCC. Patients' age was divided into the following five categories: ≤59, 60-69, 70-79, 80-84, and ≥85 years (n = 5,099, 8,809, 10,805, 2,011, and 370, respectively). The primary outcomes of hepatectomy were in-hospital death within 90 days and complications. Logistic regression analyses wer...
Source: Liver Cancer - December 12, 2017 Category: Cancer & Oncology Source Type: research

The Asia Pacific Consensus Statement on Laparoscopic Liver Resection for Hepatocellular Carcinoma: A Report from the 7th Asia-Pacific Primary Liver Cancer Expert Meeting Held in Hong Kong
Background: Laparoscopic liver resection has been gaining momentum, and it has become an accepted practice after the two international consensus conferences where experts worked up guidelines to standardize this approach and improve its safety. However, most laparoscopic hepatectomies were performed in patients with liver metastases. The concurrent presence of liver cirrhosis with hepatocellular carcinoma (HCC) poses a great challenge to clinicians trying to establish a routine use of laparoscopic liver resection for HCC.Summary: The first Asia Pacific consensus meeting on laparoscopic liver resection for HCC was held in J...
Source: Liver Cancer - December 8, 2017 Category: Cancer & Oncology Source Type: research

Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Conclusion: Loss of skeletal muscle mass is associated with increased all-cause mortality and tumor recurrence in patients with HCC. Further prospective studies incorporating measurements of muscle strength and physical function are warranted to see whether inclusion of both parameters better predicts the outcome than use of muscle mass only.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - December 8, 2017 Category: Cancer & Oncology Source Type: research

Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study
Conclusions: Axitinib/BSC did not prolong survival over placebo/BSC in non-Asians, Asians, or Asian subgroups, but favorable OS with axitinib/BSC was observed in a subset of Japanese patients. A patient population that excludes sorafenib-intolerant patients might potentially be more suitable for clinical trials of new agents in advanced HCC. Since these results are very preliminary, further investigation is warranted. The potential predictive/prognostic value of several baseline microRNAs and soluble proteins identified in this study would require validation in prospective studies on a large cohort of patients.Liver Cancer...
Source: Liver Cancer - December 7, 2017 Category: Cancer & Oncology Source Type: research

Preoperative Low Muscle Mass and Low Muscle Quality Negatively Impact on Pulmonary Function in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
Background: Sarcopenia is a prognostic factor for mortality in digestive surgery. However, the correlation between preoperative cardiopulmonary function and sarcopenia in patients undergoing hepatectomy for hepatocellular carcinoma (HCC) remains unclear.Methods: The present study investigated the impact of preoperative sarcopenia on cardiopulmonary function in 402 patients who underwent first hepatectomy for HCC between April 2005 and April 2015. The quantity and quality of skeletal muscle were evaluated using psoas muscle index (PMI) and intramuscular adipose tissue content (IMAC), respectively, as determined from preoper...
Source: Liver Cancer - December 7, 2017 Category: Cancer & Oncology Source Type: research

The APPLE Association President's Message
Liver Cancer 2017;6:381 (Source: Liver Cancer)
Source: Liver Cancer - November 16, 2017 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2017;6:380 (Source: Liver Cancer)
Source: Liver Cancer - November 16, 2017 Category: Cancer & Oncology Source Type: research

Clinical Factors Predicting Better Survival Outcome for Pulmonary Metastasectomy of Hepatocellular Carcinoma
This study aims to identify clinical factors that may be used to guide patient selection for such a therapeutic modality. A total of 28 patients who received pulmonary metastasectomy for HCC between 1993 and 2012 were identified. All relevant clinical factors were extracted from medical records up to September 2015. Patients were classified into high- and low-risk groups according to survival outcome after metastasectomy. All pertinent clinical factors were analyzed for correlation with survival outcome.Summary: The overall survivalof 28 patients after pulmonary metastasectomy was studied first. The survival curve was biph...
Source: Liver Cancer - October 28, 2017 Category: Cancer & Oncology Source Type: research

Association of Serum Ferritin with Diabetes and Alcohol in Patients with Non-Viral Liver Disease-Related Hepatocellular Carcinoma
Conclusion: In patients with nvHCC, serum ferritin levels are higher in non-diabetics and alcoholics.Liver Cancer 2017;6:307-312 (Source: Liver Cancer)
Source: Liver Cancer - October 28, 2017 Category: Cancer & Oncology Source Type: research

Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis
Conclusion: For the treatment of HCC with Vp3/Vp4, it is desirable to initially use LFP and then immediately change to sorafenib if no response is obtained.Liver Cancer 2017;6:275-286 (Source: Liver Cancer)
Source: Liver Cancer - October 25, 2017 Category: Cancer & Oncology Source Type: research

Lenvatinib in Advanced Hepatocellular Carcinoma
Liver Cancer 2017;6:253-263 (Source: Liver Cancer)
Source: Liver Cancer - October 25, 2017 Category: Cancer & Oncology Source Type: research

Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting
Background: Stereotactic body radiation therapy (SBRT) is an advanced technique of external beam radiation therapy that delivers large ablative doses of radiation. In the past decade, many cancer centers have adopted SBRT as one mode of radically treating small-sized hepatocellular carcinoma (HCC), based on encouraging clinical outcomes. SBRT thus seems reasonable as first-line treatment of inoperable HCC confined to the liver. However, most of the clinical studies to date have been retrospective in nature, with key issues still under investigation.Summary: The above-mentioned publications were subjected to scrutiny, fueli...
Source: Liver Cancer - October 25, 2017 Category: Cancer & Oncology Source Type: research

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study
Background: Level I evidence supports the use of sorafenib in patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma, where heterogeneity in efficacy exists due to varying clinicopathologic features of the disease.Aim: We evaluated whether prior treatment with curative or locoregional therapies influences sorafenib-specific survival.Methods: From a prospective data set of 785 consecutive patients from international specialist centres, 264 patients (34%) were treatment na ïve (TN) and 521 (66%) were pre-treated (PT), most frequently with transarterial chemoembolization (n = 413; 79%). The prima...
Source: Liver Cancer - October 25, 2017 Category: Cancer & Oncology Source Type: research

Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
We examined the efficacy of this grading system for determining hepatic function in patients with hepatocellular carcinoma (HCC).Methods/Materials: The prognoses of 46,681 HCC patients based on results obtained from a nationwide survey conducted in Japan from 2001 to 2007 were evaluated using (1) Japan Integrated Staging (JIS), consisting of Child-Pugh classification and TNM staging (TNM), (2) modified JIS (m-JIS), consisting of liver damage grading and TNM, and (3) ALBI-TNM (ALBI-T), consisting of ALBI grading and TNM, and the results were compared. A subanalysis was also performed to define a cutoff value for ALBI scores...
Source: Liver Cancer - October 25, 2017 Category: Cancer & Oncology Source Type: research